MedPath

Mylan Inc.

🇺🇸United States
Ownership
-
Established
1961-01-01
Employees
35K
Market Cap
-
Website
https://www.mylan.com/

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2021-12-15
Last Posted Date
2023-11-13
Lead Sponsor
Mylan Inc.
Target Recruit Count
924
Registration Number
NCT05158972
Locations
🇭🇰

Asia Priority Healthcare, Kowloon, Hong Kong

🇲🇾

Kempas Medical Center, Johor Bahru, Malaysia

🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

and more 30 locations

Study to Evaluate the Effectiveness of Legalon®

Recruiting
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Drug: Legalon® 140 mg
First Posted Date
2021-09-21
Last Posted Date
2023-04-27
Lead Sponsor
Mylan Inc.
Target Recruit Count
362
Registration Number
NCT05051527
Locations
🇹🇭

Phramongkutklao Hospital, 315 Ratchawithi Rd, Thung Phaya Thai, Ratchathewi, Bangkok, Thailand

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

Early Phase 1
Completed
Conditions
HIV-1-infection
Interventions
Combination Product: abacavir, dolutegravir and lamivudine dispersible tablets
Combination Product: Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
First Posted Date
2021-09-01
Last Posted Date
2022-03-25
Lead Sponsor
Mylan Inc.
Target Recruit Count
43
Registration Number
NCT05030025
Locations
🇨🇦

Altasciences, Montréal, Quebec, Canada

Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical

Completed
Conditions
Hypercholesterolemia
First Posted Date
2021-08-11
Last Posted Date
2023-11-07
Lead Sponsor
Mylan Inc.
Target Recruit Count
259
Registration Number
NCT05000541
Locations
🇩🇪

AmBeNet GmbH, Leipzig, Germany

🇩🇪

Medical Practice, Görlitz, Germany

🇦🇹

Ordination, Vienna, Austria

Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis

Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2021-07-26
Last Posted Date
2023-05-24
Lead Sponsor
Mylan Inc.
Target Recruit Count
130
Registration Number
NCT04976868
Locations
🇨🇳

The first Hospital of China Medical University, Shenyang, China

🇨🇳

Peking University Shenzhen Hospital, Shenzhen, China

🇨🇳

Children's Hospital Capital Institute of Pediatrics, Beijing, China

and more 7 locations

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Phase 2
Completed
Conditions
Pain, Acute
Postoperative Pain
Pain
Interventions
Drug: MR-107A-01
Drug: Placebo
First Posted Date
2020-10-01
Last Posted Date
2022-08-08
Lead Sponsor
Mylan Inc.
Target Recruit Count
114
Registration Number
NCT04571515
Locations
🇺🇸

Research Facility 101, Salt Lake City, Utah, United States

Mylan Insulin Aspart Study

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: MYL-1601D Product
Drug: FlexPen NovoLog®
First Posted Date
2018-11-30
Last Posted Date
2022-02-25
Lead Sponsor
Mylan Inc.
Target Recruit Count
478
Registration Number
NCT03760068
Locations
🇺🇸

Atlanta Diabetes Associates, Atlanta, Georgia, United States

🇺🇸

Hanson Clinical Research Center, Port Charlotte, Florida, United States

🇺🇸

Diabetes Research Center, Tustin, California, United States

and more 148 locations

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
First Posted Date
2018-06-29
Last Posted Date
2022-02-24
Lead Sponsor
Mylan Inc.
Target Recruit Count
122
Registration Number
NCT03573817
Locations
🇺🇸

Theravance Biopharma Investigational Site, Spartanburg, South Carolina, United States

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Phase 4
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Placebo
Device: Tobi Podhaler
First Posted Date
2018-04-18
Last Posted Date
2022-03-03
Lead Sponsor
Mylan Inc.
Target Recruit Count
47
Registration Number
NCT03502070
Locations
🇺🇸

Batchelor Childrens Research Institute, Miami, Florida, United States

🇺🇸

University of Miami Hospital, Miami, Florida, United States

🇺🇸

Nemours Childrens Hospital, Orlando, Florida, United States

and more 6 locations

Mylan Insulin Glargine Study

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: MYL-1501D product using manufacture process V
Drug: MYL-1501D product using manufacture process VI
First Posted Date
2017-12-18
Last Posted Date
2022-03-03
Lead Sponsor
Mylan Inc.
Target Recruit Count
219
Registration Number
NCT03376789
Locations
🇺🇸

Mylan Investigator Site, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath